{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:45:50Z","timestamp":1790217950606,"version":"4.1.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Korea Research Institute of Bioscience and Biotechnology Research Initiative Program"},{"name":"R"},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2019R1A2C1088967"],"award-info":[{"award-number":["2019R1A2C1088967"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cholinesterase (ChE) and monoamine oxidase (MAO) inhibitors have been attracted as candidate treatments for Alzheimer's disease (AD). Fifteen khellactone-type coumarins from the roots of<jats:italic>Peucedanum japonicum<\/jats:italic>Thunberg were tested for acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and MAO inhibitory activities. Compound 3\u2032-angeloyl-4\u2032-(2-methylbutyryl)khellactone (<jats:bold>PJ13<\/jats:bold>) most potently inhibited AChE (IC<jats:sub>50<\/jats:sub>\u2009=\u20099.28\u00a0\u00b5M), followed by 3\u2032-isovaleryl-4\u2032-(2-methylbutyroyl)khellactone (<jats:bold>PJ15<\/jats:bold>) (IC<jats:sub>50<\/jats:sub>\u2009=\u200910.0\u00a0\u03bcM). Compound senecioyl-4\u2032-angeloyl-khellactone (<jats:bold>PJ5<\/jats:bold>) most potently inhibited BChE (IC<jats:sub>50<\/jats:sub>\u2009=\u20097.22\u00a0\u03bcM) and had the highest selectivity index (&gt;\u20095.54), followed by 3\u2032-senecioyl-4\u2032-(2-methylbutyryl)khellactone (<jats:bold>PJ10<\/jats:bold>) and 3\u2032,4\u2032-disenecioylkhellactone (<jats:bold>PJ4<\/jats:bold>) (IC<jats:sub>50<\/jats:sub>\u2009=\u200910.2 and 10.7\u00a0\u03bcM, respectively). Compounds<jats:bold>PJ13<\/jats:bold>,<jats:bold>PJ15<\/jats:bold>, and<jats:bold>PJ5<\/jats:bold>showed reversible and mixed-types of inhibition with K<jats:sub>i<\/jats:sub>values of 5.98, 10.4 (for AChE), and 4.16\u00a0\u00b5M (for BChE), respectively. However, all 15 compounds weakly inhibited MAO-A and MAO-B. Molecular docking simulation revealed that<jats:bold>PJ13<\/jats:bold>had a higher binding affinity (\u2212\u20099.3\u00a0kcal\/mol) with AChE than<jats:bold>PJ15<\/jats:bold>(\u2212\u20097.8\u00a0kcal\/mol) or<jats:bold>PJ5<\/jats:bold>(\u2212\u00a05.4\u00a0kcal\/mol), due to the formation of a hydrogen bond with Tyr121 (distance: 2.52\u00a0\u00c5). On the other hand, the binding affinity of<jats:bold>PJ5<\/jats:bold>(\u2212\u200910.0\u00a0kcal\/mol) with BChE was higher than for<jats:bold>PJ13<\/jats:bold>(\u2212\u20097.7\u00a0kcal\/mol) or<jats:bold>PJ15<\/jats:bold>(\u2212\u20098.1\u00a0kcal\/mol), due to the formation of a hydrogen bond with Ser198 (distance: 2.05\u00a0\u00c5). These results suggest that<jats:bold>PJ13<\/jats:bold>and<jats:bold>PJ5<\/jats:bold>are potential reversible selective inhibitors of AChE and BChE, respectively, for the treatment of AD.<\/jats:p>","DOI":"10.1038\/s41598-020-78782-5","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T11:09:12Z","timestamp":1607598552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Acetylcholinesterase and butyrylcholinesterase inhibitory activities of khellactone coumarin derivatives isolated from Peucedanum japonicum Thurnberg"],"prefix":"10.1038","volume":"10","author":[{"given":"Jeong Hyun","family":"Heo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Hyun","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Won","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Gyun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Eun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doo-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daeui","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sei-Ryang","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,10]]},"reference":[{"key":"78782_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ejmech.2013.09.050","volume":"70","author":"M Singh","year":"2013","unstructured":"Singh, M. et al. Acetylcholinesterase inhibitors as Alzheimer therapy: From nerve toxins to neuroprotection. Eur. J. Med. Chem. 70, 165\u2013188 (2013).","journal-title":"Eur. J. Med. Chem."},{"key":"78782_CR2","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2174\/1389557520666200103100521","volume":"20","author":"H Ak\u0131nc\u0131o\u011flu","year":"2020","unstructured":"Ak\u0131nc\u0131o\u011flu, H. & G\u00fcl\u00e7in, \u0130. Potent acetylcholinesterase inhibitors: potential drugs for Alzheimer\u2019s disease. Mini Rev. Med. Chem. 20, 703\u2013715 (2020).","journal-title":"Mini Rev. Med. Chem."},{"key":"78782_CR3","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/S0047-6374(01)00309-8","volume":"122","author":"VN Talesa","year":"2001","unstructured":"Talesa, V. N. Acetylcholinesterase in Alzheimer\u2019s disease. Mech. Ageing Dev. 122, 1961\u20131969 (2001).","journal-title":"Mech. Ageing Dev."},{"key":"78782_CR4","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/B978-0-12-386525-0.00132-3","volume-title":"Primer on the Autonomic Nervous System","author":"BA English","year":"2012","unstructured":"English, B. A. & Webster, A. A. Acetylcholinesterase and its inhibitors. In Primer on the Autonomic Nervous System 3rd edn (eds Robertson, D. et al.) 631\u2013633 (Academic Press, Cambridge, 2012).","edition":"3"},{"key":"78782_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/1570159X11311030006","volume":"11","author":"MB Colovi\u0107","year":"2013","unstructured":"Colovi\u0107, M. B., Krsti\u0107, D. Z., Lazarevi\u0107-Pa\u0161ti, T. D., Bond\u017ei\u0107, A. M. & Vasi\u0107, V. M. Acetylcholinesterase inhibitors: Pharmacology and toxicology. Curr. Neuropharmacol. 11, 315\u2013335 (2013).","journal-title":"Curr. Neuropharmacol."},{"key":"78782_CR6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1046\/j.1365-2125.1999.00026.x","volume":"48","author":"BM McGleenon","year":"1999","unstructured":"McGleenon, B. M., Dynan, K. B. & Passmore, A. P. Acetylcholinesterase inhibitors in Alzheimer\u2019s disease. Br. J. Clin. Pharmacol. 48, 471\u2013480 (1999).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"78782_CR7","unstructured":"Kumar A. & Sharma S. Donepezil. NCBI Bookshelf. Last Update: April 21, (2020)."},{"key":"78782_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/ciia.2007.2.1.17","volume":"2","author":"ML Onor","year":"2007","unstructured":"Onor, M. L., Trevisiol, M. & Aguglia, A. Rivastigmine in the treatment of Alzheimer\u2019s disease: an update. Clin. Interv. Aging 2, 17\u201332 (2007).","journal-title":"Clin. Interv. Aging"},{"key":"78782_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1527-3458.2002.tb00237.x","volume":"8","author":"DS Woodruff-Pak","year":"2002","unstructured":"Woodruff-Pak, D. S., Lander, C. & Geerts, H. Nicotinic cholinergic modulation: Galantamine as a prototype. CNS Drug Rev. 8, 405\u2013426 (2002).","journal-title":"CNS Drug Rev."},{"key":"78782_CR10","first-page":"45","volume":"127","author":"F Inglis","year":"2002","unstructured":"Inglis, F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int. J. Clin. Pract. Suppl. 127, 45\u201363 (2002).","journal-title":"Int. J. Clin. Pract. Suppl."},{"key":"78782_CR11","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1038\/s41598-018-22747-2","volume":"8","author":"A Kumar","year":"2018","unstructured":"Kumar, A. et al. Novel 2-pheynylbenzofuran derivatives as selective butyrylcholinesterase inhibitors for Alzheimer\u2019s disease. Sci. Rep. 8, 4424 (2018).","journal-title":"Sci. Rep."},{"key":"78782_CR12","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2174\/1567205013666160404120542","volume":"13","author":"S Darvesh","year":"2016","unstructured":"Darvesh, S. Butyrylcholinesterase as a diagnostic and therapeutic target for Alzheimer\u2019s disease. Curr. Alzheimer Res. 13, 1173\u20131177 (2016).","journal-title":"Curr. Alzheimer Res."},{"key":"78782_CR13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2217\/bmm.13.37","volume":"7","author":"F Lake","year":"2013","unstructured":"Lake, F. BChE reported to be associated with plaque level in Alzheimer\u2019s disease. Biomark Med. 7, 197\u2013198 (2013).","journal-title":"Biomark Med."},{"key":"78782_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3389\/fnins.2016.00375","volume":"10","author":"RR Ramsay","year":"2016","unstructured":"Ramsay, R. R., Majekova, M., Medina, M. & Valoti, M. Key targets for multi-target ligands designed to combat neurodegeneration. Front. Neurosci. 10, 375 (2016).","journal-title":"Front. Neurosci."},{"key":"78782_CR15","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/1062936X.2018.1423641","volume":"29","author":"BP Repsold","year":"2018","unstructured":"Repsold, B. P., Malan, S. F., Joubert, J. & Oliver, D. W. Multi-targeted directed ligands for Alzheimer\u2019s disease: Design of novel lead coumarin conjugates. SAR QSAR Environ. Res. 29, 231\u2013255 (2018).","journal-title":"SAR QSAR Environ. Res."},{"key":"78782_CR16","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1039\/C8MD00399H","volume":"9","author":"B Mathew","year":"2018","unstructured":"Mathew, B. et al. Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors. Med. Chem. Comm. 9, 1871\u20131881 (2018).","journal-title":"Med. Chem. Comm."},{"key":"78782_CR17","doi-asserted-by":"publisher","first-page":"e1800309","DOI":"10.1002\/ardp.201800309","volume":"352","author":"B Mathew","year":"2019","unstructured":"Mathew, B. et al. Potent and highly selective dual-targeting monoamine oxidase-B inhibitors: fluorinated chalcones of morpholine versus imidazole. Arch. Pharm. 352, e1800309 (2019).","journal-title":"Arch. Pharm."},{"key":"78782_CR18","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2174\/1871527318666190906101326","volume":"18","author":"BSC Reeta","year":"2019","unstructured":"Reeta, B. S. C. et al. Ethyl acetohydroxamate incorporated chalcones: unveiling a novel class of chalcones for multitarget monoamine oxidase-B inhibitors against Alzheimer\u2019s disease. CNS Neurol. Disord. Drug Targets 18, 643\u2013654 (2019).","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"78782_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ejmech.2019.05.039","volume":"177","author":"B Kumar","year":"2019","unstructured":"Kumar, B. et al. Dipropargyl substituted diphenylpyrimidines as dual inhibitors of monoamine oxidase and acetylcholinesterase. Eur. J. Med. Chem. 177, 221\u2013234 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"78782_CR20","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.2174\/0929867043364810","volume":"15","author":"KF Tipton","year":"2004","unstructured":"Tipton, K. F., Boyce, S., O\u2019Sullivan, J., Davey, G. P. & Healy, J. Monoamine oxidases: certainties and uncertainties. Curr. Med. Chem. 15, 1965\u20131982 (2004).","journal-title":"Curr. Med. Chem."},{"key":"78782_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-981-10-7757-9_5","volume":"87","author":"DE Edmondson","year":"2018","unstructured":"Edmondson, D. E. & Binda, C. Monoamine oxidases. Subcell. Biochem. 87, 117\u2013139 (2018).","journal-title":"Subcell. Biochem."},{"key":"78782_CR22","first-page":"42","volume":"28","author":"MA Cristancho","year":"2011","unstructured":"Cristancho, M. A., O\u2019reardon, J. P. & Thase, M. E. Atypical depression in the 21st century: Diagnostic and treatment issues. Psychiatric Times 28, 42\u201347 (2011).","journal-title":"Psychiatric Times"},{"key":"78782_CR23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2174\/1871527316666170124165222","volume":"16","author":"L Dezsi","year":"2017","unstructured":"Dezsi, L. & Vecsei, L. Monoamine oxidase B inhibitors in Parkinson\u2019s disease. CNS Neurol. Disord. Drug Targets 16, 425\u2013439 (2017).","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"78782_CR24","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/S0196-9781(02)00062-1","volume":"23","author":"MH Tran","year":"2002","unstructured":"Tran, M. H., Yamada, K. & Nabeshima, T. Amyloid beta-peptide induces cholinergic dysfunction and cognitive deficits: a minireview. Peptides 23, 1271\u20131283 (2002).","journal-title":"Peptides"},{"key":"78782_CR25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.bbr.2008.03.002","volume":"190","author":"H Tsunekawa","year":"2008","unstructured":"Tsunekawa, H., Noda, Y., Mouri, A., Yoneda, F. & Nabeshima, T. Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25\u201335). Behav. Brain Res. 190, 224\u2013232 (2008).","journal-title":"Behav. Brain Res."},{"key":"78782_CR26","doi-asserted-by":"publisher","first-page":"7835","DOI":"10.3892\/mmr.2017.7502","volume":"16","author":"Z Li","year":"2017","unstructured":"Li, Z. et al. Xanomeline derivative EUK1001 attenuates Alzheimer\u2019s disease pathology in a triple transgenic mouse model. Mol. Med. Rep. 16, 7835\u20137840 (2017).","journal-title":"Mol. Med. Rep."},{"key":"78782_CR27","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.3892\/mmr.2014.2040","volume":"9","author":"Z Cai","year":"2014","unstructured":"Cai, Z. Monoamine oxidase inhibitors: Promising therapeutic agents for Alzheimer\u2019s disease (review). Mol. Med. Rep. 9, 1533\u20131541 (2014).","journal-title":"Mol. Med. Rep."},{"key":"78782_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jep.2014.08.034","volume":"156","author":"P Sarkhail","year":"2014","unstructured":"Sarkhail, P. Traditional uses, phytochemistry and pharmacological properties of the genus Peucedanum: A review. J. Ethnopharmacol. 156, 235\u2013270 (2014).","journal-title":"J. Ethnopharmacol."},{"key":"78782_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.5963\/LSMR0202004","volume":"2","author":"N Nukitrangsan","year":"2012","unstructured":"Nukitrangsan, N. et al. Anti-obesity activity of Peucedanum japonicum Thunb extract in obese diabetic animal model C57BL\/6J Ham Slc-ob\/ob mice. Int. J. Life Sci. Med. Res. 2, 28\u201334 (2012).","journal-title":"Int. J. Life Sci. Med. Res."},{"key":"78782_CR30","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/ptr.3355","volume":"25","author":"T Okabe","year":"2011","unstructured":"Okabe, T. et al. Peucedanum japonicum Thunb inhibits high-fat diet induced obesity in mice. Phytother. Res. 25, 870\u2013877 (2011).","journal-title":"Phytother. Res."},{"key":"78782_CR31","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1016\/j.bmcl.2016.08.056","volume":"26","author":"RY Choi","year":"2016","unstructured":"Choi, R. Y. et al. Anti-adipogenic and anti-diabetic effects of cis-3\u2032,4\u2032-diisovalerylkhellactone isolated from Peucedanum japonicum Thunb leaves in vitro. Bioorg. Med. Chem. Lett. 26, 4655\u20134660 (2016).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"78782_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3344\/kjp.2017.30.2.98","volume":"30","author":"SH Kim","year":"2017","unstructured":"Kim, S. H., Jong, H. S., Yoon, M. H., Oh, S. H. & Jung, K. T. Antinociceptive effect of intrathecal sec-O-glucosylhamaudol on the formalin-induced pain in rats. Korean J. Pain 30, 98\u2013103 (2017).","journal-title":"Korean J. Pain"},{"key":"78782_CR33","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3892\/etm.2017.4480","volume":"14","author":"JM Kim","year":"2017","unstructured":"Kim, J. M. et al. Peucedanum japonicum thunb Ethanol extract suppresses RANKL-mediated osteoclastogenesis. Exp. Ther. Med. 14, 410\u2013416 (2017).","journal-title":"Exp. Ther. Med."},{"key":"78782_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jep.2017.09.006","volume":"211","author":"JM Chun","year":"2018","unstructured":"Chun, J. M. et al. Peucedanum japonicum extract attenuates allergic airway inflammation by inhibiting Th2 cell activation and production of pro-inflammatory mediators. J. Ethnopharmacol. 211, 78\u201388 (2018).","journal-title":"J. Ethnopharmacol."},{"key":"78782_CR35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.7231\/jon.2013.24.1.123","volume":"24","author":"KN Kim","year":"2013","unstructured":"Kim, K. N., Choi, M. J., Lee, Y. & Cho, S. H. The protective and recovery effects of Peucedanum Japonicum Thunberg for vascular dementia. J. Orient Neuropsychiatry 24, 123\u2013130 (2013).","journal-title":"J. Orient Neuropsychiatry"},{"key":"78782_CR36","doi-asserted-by":"publisher","first-page":"5255","DOI":"10.1021\/jf0262458","volume":"51","author":"M Hisamoto","year":"2003","unstructured":"Hisamoto, M., Kikuzaki, H., Ohigashi, H. & Nakatani, N. Antioxidant compounds from the leaves of Peucedanum japonicum thunb. J. Agric. Food Chem. 51, 5255\u20135261 (2003).","journal-title":"J. Agric. Food Chem."},{"key":"78782_CR37","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1021\/jf0349127","volume":"52","author":"M Hisamoto","year":"2004","unstructured":"Hisamoto, M., Kikuzaki, H. & Nakatani, N. Constituents of the leaves of Peucedanum japonicum thunb. and their biological activity. J. Agric. Food Chem. 52, 445\u2013450 (2004).","journal-title":"J. Agric. Food Chem."},{"key":"78782_CR38","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/BF02975882","volume":"27","author":"SO Lee","year":"2004","unstructured":"Lee, S. O. et al. Antidiabetic coumarin and cyclitol compounds from Peucedanum japonicum. Arch. Pharm. Res. 27, 1207\u20131210 (2004).","journal-title":"Arch. Pharm. Res."},{"key":"78782_CR39","doi-asserted-by":"publisher","first-page":"121835","DOI":"10.1016\/j.jchromb.2019.121835","volume":"1133","author":"HJ Won","year":"2019","unstructured":"Won, H. J. et al. Rapid securing of reference substances from Peucedanum japonicum Thunberg.z by recycling preparative high-performance liquid chromatography. J. Chromatography B 1133, 121835 (2019).","journal-title":"J. Chromatography B"},{"key":"78782_CR40","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.bioorg.2018.10.051","volume":"83","author":"SC Baek","year":"2019","unstructured":"Baek, S. C. et al. Rhamnocitrin isolated from Prunus padus var. seoulensis: A potent and selective reversible inhibitor of human monoamine oxidase A. Bioorg. Chem. 83, 317\u2013325 (2019).","journal-title":"Bioorg. Chem."},{"key":"78782_CR41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","volume":"7","author":"GL Ellman","year":"1961","unstructured":"Ellman, G. L., Courtney, K. D., Andres, V. Jr. & Featherstone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7, 88\u201395 (1961).","journal-title":"Biochem. Pharmacol."},{"key":"78782_CR42","doi-asserted-by":"publisher","first-page":"103043","DOI":"10.1016\/j.bioorg.2019.103043","volume":"89","author":"JP Lee","year":"2019","unstructured":"Lee, J. P. et al. Potent inhibition of acetylcholinesterase by sargachromanol I from Sargassum siliquastrum and by selected natural compounds. Bioorg. Chem. 89, 103043 (2019).","journal-title":"Bioorg. Chem."},{"key":"78782_CR43","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.1016\/j.bmcl.2016.08.044","volume":"26","author":"HW Lee","year":"2016","unstructured":"Lee, H. W. et al. Potent selective monoamine oxidase B inhibition by maackiain, a pterocarpan from the roots of Sophora flavescens. Bioorg. Med. Chem. Lett. 26, 4714\u20134719 (2016).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"78782_CR44","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.bmcl.2018.01.049","volume":"28","author":"SC Baek","year":"2018","unstructured":"Baek, S. C. et al. Selective inhibition of monoamine oxidase A by hispidol. Bioorg. Med. Chem. Lett. 28, 584\u2013588 (2018).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"78782_CR45","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455\u2013461 (2010).","journal-title":"J. Comput. Chem."},{"key":"78782_CR46","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera\u2014A visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."},{"key":"78782_CR47","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/BF00134183","volume":"10","author":"JEJ Mills","year":"1996","unstructured":"Mills, J. E. J. & Dean, P. M. Three-dimensional hydrogen-bond geometry and probability information from a crystal survey. J. Comput. Aided Mol Des. 10, 607\u2013622 (1996).","journal-title":"J. Comput. Aided Mol Des."},{"key":"78782_CR48","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina, A., Michielin, O. & Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7, 42717 (2017).","journal-title":"Sci. Rep."},{"key":"78782_CR49","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.3389\/fphar.2018.01192","volume":"9","author":"TC dos Santos","year":"2018","unstructured":"dos Santos, T. C., Gomes, T. M., Pinto, B. A. S., Camara, A. L. & de Andrade, P. A. M. Naturally occurring acetylcholinesterase inhibitors and their potential use for Alzheimer\u2019s disease therapy. Front. Pharmacol. 9, 1192 (2018).","journal-title":"Front. Pharmacol."},{"key":"78782_CR50","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jep.2018.11.009","volume":"231","author":"OS Ajayi","year":"2019","unstructured":"Ajayi, O. S., Aderogba, M. A., Obuotor, E. M. & Majinda, R. R. T. Acetylcholinesterase inhibitor from Anthocleista vogelii leaf extracts. J. Ethnopharmacol. 231, 503\u2013506 (2019).","journal-title":"J. Ethnopharmacol."},{"key":"78782_CR51","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.3390\/12092130","volume":"12","author":"M Jung","year":"2007","unstructured":"Jung, M. & Park, M. Acetylcholinesterase inhibition by flavonoids from Agrimoniapilosa. Molecules 12, 2130\u20132139 (2007).","journal-title":"Molecules"},{"key":"78782_CR52","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1007\/s12272-013-0316-y","volume":"37","author":"YH Bae","year":"2014","unstructured":"Bae, Y. H. et al. Cholinesterase inhibitors from the roots of Harpagophytum procumbens. Arch. Pharm. Res. 37, 1124\u20131129 (2014).","journal-title":"Arch. Pharm. Res."},{"key":"78782_CR53","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/BF02980046","volume":"27","author":"JH Lee","year":"2004","unstructured":"Lee, J. H., Lee, K. T., Yang, J. H., Baek, N. I. & Kim, D. K. Acetylcholinesterase inhibitors from the twigs of Vaccinium oldhami Miquel. Arch. Pharm. Res. 27, 53\u201356 (2004).","journal-title":"Arch. Pharm. Res."},{"key":"78782_CR54","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1021\/np000441w","volume":"64","author":"SY Kang","year":"2001","unstructured":"Kang, S. Y., Lee, K. Y., Sung, S. H., Park, M. J. & Kim, Y. C. Coumarins isolated from Angelica gigas inhibit acetylcholinesterase: Structure-activity relationships. J. Nat. Prod. 64, 683\u2013685 (2001).","journal-title":"J. Nat. Prod."},{"key":"78782_CR55","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/ptr.3576","volume":"26","author":"N Changwong","year":"2012","unstructured":"Changwong, N., Sabphon, C., Ingkaninan, K. & Sawasdee, P. Acetyl- and butyryl-cholinesterase inhibitory activities of mansorins and mansonones. Phytother. Res. 26, 392\u2013396 (2012).","journal-title":"Phytother. Res."},{"key":"78782_CR56","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.apjtm.2016.01.014","volume":"9","author":"MY Ali","year":"2016","unstructured":"Ali, M. Y. et al. Anti-Alzheimer\u2019s disease potential of coumarins from Angelica decursiva and Artemisia capillaris and structure-activity analysis. Asian Pac. J. Trop. Med. 9, 103\u2013111 (2016).","journal-title":"Asian Pac. J. Trop. Med."},{"key":"78782_CR57","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1021\/np100531x","volume":"73","author":"J Youkwan","year":"2010","unstructured":"Youkwan, J., Sutthivaiyakit, S. & Sutthivaiyakit, P. Citrusosides A\u2212D and furanocoumarins with cholinesterase inhibitory activity from the fruit peels of Citrus hystrix. J. Nat. Prod. 73, 1879\u20131883 (2010).","journal-title":"J. Nat. Prod."},{"key":"78782_CR58","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s12272-018-1056-9","volume":"41","author":"MY Ali","year":"2018","unstructured":"Ali, M. Y., Seong, S. H., Jung, H. A., Jannat, S. & Choi, J. S. Kinetics and molecular docking of dihydroxanthyletin-type coumarins from Angelica decursiva that inhibit cholinesterase and BACE1. Arch. Pharm. Res. 41, 753\u2013764 (2018).","journal-title":"Arch. Pharm. Res."},{"key":"78782_CR59","doi-asserted-by":"publisher","first-page":"7873","DOI":"10.1016\/j.bmc.2010.09.044","volume":"18","author":"K Awang","year":"2010","unstructured":"Awang, K. et al. 4-Phenylcoumarins from Mesua elegans with acetylcholinesterase inhibitory activity. Bioorg. Med. Chem. 18, 7873\u20137877 (2010).","journal-title":"Bioorg. Med. Chem."},{"key":"78782_CR60","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/ph10040084","volume":"10","author":"J Calva","year":"2017","unstructured":"Calva, J. et al. Acorenone B: AChE and BChE inhibitor as a major compound of the essential oil distilled from the Ecuadorian species Niphogeton dissecta (Benth.) J.F. Macbr. Pharmaceuticals 10, 84 (2017).","journal-title":"Pharmaceuticals"},{"key":"78782_CR61","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s12272-010-1016-5","volume":"33","author":"BS Min","year":"2010","unstructured":"Min, B. S. et al. Cholinesterase inhibitors from Cleistocalyx operculatus buds. Arch. Pharm. Res. 33, 1665\u20131670 (2010).","journal-title":"Arch. Pharm. Res."},{"key":"78782_CR62","doi-asserted-by":"publisher","first-page":"e1900017","DOI":"10.1002\/cbdv.201900017","volume":"16","author":"IE Orhan","year":"2019","unstructured":"Orhan, I. E. et al. Profiling auspicious butyrylcholinesterase inhibitory activity of two herbal molecules: hyperforin and hyuganin C. Chem. Biodivers. 16, e1900017 (2019).","journal-title":"Chem. Biodivers."},{"key":"78782_CR63","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.fct.2017.03.016","volume":"109","author":"IE Orhan","year":"2017","unstructured":"Orhan, I. E., Senol, F. S., Shekfeh, S., Skalicka-Wozniak, K. & Banoglu, E. Pteryxin\u2014A promising butyrylcholinesterase-inhibiting coumarin derivative from Mutellina purpurea. Food Chem. Toxicol. 109, 970\u2013974 (2017).","journal-title":"Food Chem. Toxicol."},{"key":"78782_CR64","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.bmc.2011.12.042","volume":"20","author":"P Anand","year":"2012","unstructured":"Anand, P., Singh, B. & Singh, N. A review on coumarins as acetylcholinesterase inhibitors for Alzheimer\u2019s disease. Bioorg. Med. Chem. 20, 1175\u20131180 (2012).","journal-title":"Bioorg. Med. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78782-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78782-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78782-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T22:12:11Z","timestamp":1698444731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78782-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,10]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["78782"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-78782-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,10]]},"assertion":[{"value":"15 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21695"}}